Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 141

Sort by

Sort Order Select

Journal Articles

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

Blood (2024) 143 (14): 1399–1413.

https://doi.org/10.1182/blood.2023021349

Published: 2024

Includes: Supplemental data

Journal Articles

First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis

Blood (2023) 142 (Supplement 1): 4135.

https://doi.org/10.1182/blood-2023-189094

Published: 2023

Journal Articles

Safety and Efficacy of New Drugs Combinations in Newly Diagnosed Multiple Myeloma with Renal Failure at Onset: A Retrospective Multicentric Study

Antonio Frolli, Claudio Cerchione, Riccardo Staiano, Tommasina Guglielmelli, Davide Nappi, Agnese Mattei, Silvia Marini, Daniela Cilloni, Guido Eugenio Parvis

Blood (2023) 142 (Supplement 1): 6656.

https://doi.org/10.1182/blood-2023-190212

Published: 2023

Journal Articles

Mylox-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis

Srdan Verstovsek, John Mascarenhas, Raajit K Rampal, Daniela Cilloni, Claire Harrison, Brian Jacoby, Robert J. Slack, Vassilios Aslanis, Bobby Singh, Bertil Lindmark

Blood (2022) 140 (Supplement 1): 3868–3870.

https://doi.org/10.1182/blood-2022-167496

Published: 2022

Journal Articles

A Radiation-Free Approach Based on the Whole-Body-MRI Has Shown a High Level of Accuracy in the Follow up of Lymphoma Patients. a Single Center Retrospective Study

Antonio Frolli, Silvia Varvello, Annalisa Balbo Mussetto, Daniela Gottardi, Martina Bullo, Silvia Marini, Giuseppe Saglio, Stefano Cirillo, Daniela Cilloni, Guido Eugenio Parvis

Blood (2022) 140 (Supplement 1): 9317.

https://doi.org/10.1182/blood-2022-168519

Published: 2022

Journal Articles

Patient Specific Droplet Digital PCR Targeting FLT3-ITD Allows to Detect Small Clones in Acute Leukemias at Diagnosis and during Follow-up

Daniela Cilloni, Johanna Umurungi, Valentina Bonuomo, Federico Itri, Cristina Rotolo, Silvia Marini, Monia Lunghi, Andrea Castelli, Carmen Fava, Giuseppe Saglio, Alessandro Cignetti, Jessica Petiti

Blood (2022) 140 (Supplement 1): 11827–11828.

https://doi.org/10.1182/blood-2022-167017

Published: 2022

Journal Articles

Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Blood (2022) 140 (Supplement 1): 9685–9687.

https://doi.org/10.1182/blood-2022-156371

Published: 2022

Journal Articles

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Luca Lanino, Prassede Salutari, Alessandra Perego, Bruno Fattizzo, Marta Riva, Marta Ubezio, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Maria Teresa Voso, Anna Maria Pelizzari, Antonella Poloni, Isabella Capodanno, Chiara Elena, Claudio Fozza, Fabrizio Pane, Massimo Breccia, Marco De Gobbi, Francesco Di Bassiano, Daniela Barraco, Elena Crisà, Dario Ferrero, Chiara Frairia, Antonella Vaccarino, Davide Griguolo, Stefania Paolini, Martina Quintini, Mariarosaria Sessa, Mauro Turrini, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Cristina Foli, Alfredo Molteni, Ubaldo Occhini, Giulia Rivoli, Carmine Selleri, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Alessandro Rambaldi, Ilaria Tanasi, Patrizia Tosi, Ilaria Naldi, Valeria Santini, Matteo G. Della Porta

Blood (2022) 140 (Supplement 1): 6945–6948.

https://doi.org/10.1182/blood-2022-164559

Published: 2022

Journal Articles

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Blood (2022) 140 (Supplement 1): 9688–9690.

https://doi.org/10.1182/blood-2022-157914

Published: 2022

Journal Articles

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 2351.

https://doi.org/10.1182/blood-2021-144912

Published: 2021

Journal Articles

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

Blood (2021) 138 (Supplement 1): 3624.

https://doi.org/10.1182/blood-2021-152420

Published: 2021

Journal Articles

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-139981

Published: 2020

Journal Articles

A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

Carmen Fava, Paola Berchialla, PhD, Jessica Petiti, PhD, Maria Teresa Bochicchio, Barbara Izzo, PhD, Emilia Giugliano, Emanuela Ottaviani, Santa Errichiello, PhD, Giovanna Rege Cambrin, MD PhD, Claudia Venturi, Luigiana Luciano, Filomena Daraio, Daniele Calistri, Alessandro Martino, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Fabrizio Pane, MD, Daniela Cilloni, MD PhD, Enrico Marco Gottardi

Blood (2019) 134 (Supplement_1): 2092.

https://doi.org/10.1182/blood-2019-125614

Published: 2019

Journal Articles

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

Blood (2019) 134 (Supplement_1): 839.

https://doi.org/10.1182/blood-2019-127488

Published: 2019

Journal Articles

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Emanuele Angelucci, MD, Mario Capasso, PhD, Matteo Giovanni Della Porta, MD, Gian Luca Forni, Domenico Girelli, MD, PhD, Esther Natalie Oliva, MD, Federica Pilo, MD, Marino Clavio, MD, Marta Riva, MD, Annamaria Pelizzari, MD, Pasquale Niscola, MD PhD, Daniela Cilloni, MD PhD, Gianni Binotto, MD, Elena Crisà, MD, Valeria Santini, MD

Blood (2019) 134 (Supplement_1): 4256.

https://doi.org/10.1182/blood-2019-125575

Published: 2019

Journal Articles

Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study

Paola Guglielmelli, MD PhD, Francesca Palandri, PhD MD, Carmine Selleri, MD, Daniela Cilloni, MD PhD, Francesco Mendicino, MD, Patrizio Mazza, MD, Domenico Pastore, MD PhD, Giuseppe A. Palumbo, MD, Sergio Siragusa, Prof, MD, Vincenzo Pavone, Stefana Impera, MD, Mara Morelli, MD, Francesco Passamonti, MD, Massimo Breccia, MD

Blood (2019) 134 (Supplement_1): 4179.

https://doi.org/10.1182/blood-2019-124730

Published: 2019

Journal Articles

Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI)

Massimo Breccia, MD, Paola Guglielmelli, MD PhD, Alessandra Malato, MD, Francesco Mendicino, MD, Giuseppe A. Palumbo, MD, Carmine Selleri, MD, Daniela Cilloni, MD PhD, Patrizio Mazza, MD, Sergio Siragusa, MD Professor, Elisabetta Abruzzese, Roberto Latagliata, Monica Crugnola, MD, Domenico Pastore, MD PhD, Giorgia Micucci, MD, Giulia Benevolo, MD, Mara Morelli, MD, Francesca Palandri, PhD MD, Francesco Passamonti

Blood (2018) 132 (Supplement 1): 4312.

https://doi.org/10.1182/blood-2018-99-110198

Published: 2018

Journal Articles

Long Term AML Survivors Have Increased Mortality and High Prevalence of Clonal Hematopoiesis

Noa Chapal Ilani, PhD, Elisabeth Niemeyer, MD, Netta Mendelson Cohen, PhD, Yoni Moskovitz, PhD, Barak Oron, Amanda Mitchell, PhD, Mark D. Minden, MD PhD, Amos Tanay, PhD, Ran Balicer, MD PhD, Tamir Biezuner, PhD, Daniela Cilloni, MD PhD, Klaus H. Metzeler, MD, Yishai Ofran, MD, Nathali Kaushansky, PhD, Liran I. Shlush, MD PhD

Blood (2018) 132 (Supplement 1): 1287.

https://doi.org/10.1182/blood-2018-99-116599

Published: 2018

Journal Articles

Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

Jaap Jan Boelens, MD PhD, Coco de Koning, Mitchell E. Horwitz, MD, Guillermo Sanz, Madan Jagasia, MD MS, John E. Wagner, MD, Patrick J. Stiff, MD, Rabi Hanna, MD, Daniela Cilloni, MD PhD, Stefan Nierkens, PhD

Blood (2018) 132 (Supplement 1): 2123.

https://doi.org/10.1182/blood-2018-99-116700

Published: 2018

Journal Articles

Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome

Blood (2018) 132 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2018-99-118123

Published: 2018

NARROW

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis

Safety and Efficacy of New Drugs Combinations in Newly Diagnosed Multiple Myeloma with Renal Failure at Onset: A Retrospective Multicentric Study

Mylox-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis

A Radiation-Free Approach Based on the Whole-Body-MRI Has Shown a High Level of Accuracy in the Follow up of Lymphoma Patients. a Single Center Retrospective Study

Patient Specific Droplet Digital PCR Targeting FLT3-ITD Allows to Detect Small Clones in Acute Leukemias at Diagnosis and during Follow-up

Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study

Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI)

Long Term AML Survivors Have Increased Mortality and High Prevalence of Clonal Hematopoiesis

Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only